Although ~ 25% of colorectal cancer or polyp (CRC/P) cases show familial aggregation, current germline genetic testing identifies a causal genotype in the 16 major genes associated with high penetrance CRC/P in only 20% of these cases. As there are likely other genes underlying heritable CRC/P, we evaluated the association of variation at novel loci with CRC/P. We evaluated 158 a priori selected candidate genes by comparing the number of rare potentially disruptive variants (PDVs) found in 84 CRC/P cases without an identified CRC/P risk-associated variant and 2440 controls. We repeated this analysis using an additional 73 CRC/P cases. We also compared the frequency of PDVs in select genes among CRC/P cases with two publicly available data sets. We found a significant enrichment of PDVs in cases vs. controls: 20% of cases vs. 11.5% of controls with ≥ 1 PDV (OR = 1.9, p = 0.01) in the original set of cases. Among the second cohort of CRC/P cases, 18% had a PDV, significantly different from 11.5% (p = 0.02). Logistic regression, adjusting for ancestry and multiple testing, indicated association between CRC/P and PDVs in NTHL1 (p = 0.0001), BRCA2 (p = 0.01) and BRIP1 (p = 0.04). However, there was no significant difference in the frequency of PDVs at each of these genes between all 157 CRC/P cases and two publicly available data sets. These results suggest an increased presence of PDVs in CRC/P cases and support further investigation of the association of NTHL1, BRCA2 and BRIP1 variation with CRC/P.
Introduction
Colorectal cancer (CRC) is the third most common and second most lethal cancer in the United States (Howlader et al. 2016) . In 2016, CRC was estimated to be newly
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The online version of this article (https ://doi.org/10.1007/s0043 9-018-1938-4) contains supplementary material, which is available to authorized users. diagnosed in ~ 134,000 individuals in the United States (Howlader et al. 2016) . The lifetime risk of developing CRC is ~ 4.5% (Howlader et al. 2016) . Without CRC screening, this risk doubles for individuals with a single affected first-degree relative, and increases further with additional affected first-degree relatives (Fuchs et al. 1994 (Fuchs et al. , 1669 (Fuchs et al. -1674 . At present, about 5% of all CRC cases can be attributed to a pathogenic variant in genes known to be associated with increased CRC risk (Patel and Ahnen 2012, 428-438) .
There are several high penetrance Mendelian genes whose germline variants are known to be associated with CRC, which generally develops from adenomatous polyps or serrated polyps (Levin et al. 2008, 130-160 (Nishisho et al. 1991, 665-669; Malkin et al. 1990 Malkin et al. , 1233 Malkin et al. -1238 Jenne et al. 1998, 38-43) . Pathogenic variants that predispose to CRC/P have also been identified in POLE [MIM 174762] and POLD1 [MIM 174761 ] (Palles et al. 2013, 136-144) and are inherited in an autosomal-dominant pattern. Recessive mode of inheritance of CRC/P is attributable to pathogenic variants in MUTYH [MIM 604933] , associated with tens to hundreds of polyps and possibly the more recently reported NTHL1 [MIM 602656] and MSH3 [MIM 600887 ] (Jones et al. 2002 (Jones et al. , 2961 (Jones et al. -2967 Weren et al. 2015, 668-671; Adam et al. 2016, 337-351) .
In addition to the 5% of CRC/P cases that can be explained by a germline pathogenic variant, another ~ 20-25% of all CRC/P cases appear familial, but do not have a causal variant identified by current genetic testing (Lynch and de la Chapelle 1999, 801-818; Patel and Ahnen 2012, 428-438; PDQ Cancer Genetics Editorial Board 2002) . Failure to detect a genetic etiology for these patients may be due to one of several reasons. First, the underlying cause may be sporadic in multiple relatives, rather than hereditary (Lichtenstein et al. 2000, 78-85) , resulting in phenocopies. Second, germline genetic panel testing may detect variants of uncertain significance (VUS) which are truly pathogenic, but their pathogenicity is not yet established. Third, technical issues may result in a false-negative genetic finding. Fourth, low-penetrance common variants account for some portion of CRC/P (Peters et al. 2012, 217-234; Hes et al. 2014, 55-60) . Finally, as pathogenic variants in other known cancer associated genes from broader panels have been found in such patients, there may be other highly penetrant pathogenic variants in genes underlying heritable CRC/P that have not been identified or validated and are not included on current CRC/P-specific genetic testing panels (AlDubayan et al. 2018, 401-414) .
Several thousand genes have been proposed to be involved in CRC/P risk. These include genes involved in DNA repair pathways and other cancer-related biological pathways, and genes implicated by GWAS or familial linkage (Hes et al. 2014, 55-60; Gylfe et al. 2013, e1003876; Smith et al. 2013 Smith et al. , 1026 Smith et al. -1034 . We set out to narrow this list of candidate genes to test for evidence of novel CRC/P-associated genes. Identification of such genes would allow for improved diagnostic testing using evolving CRC/P germline genetic testing panels.
Materials and methods

Participants: original cohorts
Ninety-two participants with CRC/P and of European ancestry (EA) were ascertained from three sources: The Clinical Sequencing Exploratory Research consortium, New EXome Technology in Medicine study (CSER) (N = 57) at the University of Washington (UW), the Northwest Institute of Genetic Medicine Family Polyps Study (PP) (N = 10) at UW, and the Women's Health Initiative (WHI) (N = 25). Participants from CSER and PP were ascertained through referral to the UW Genetic Medicine clinic and will be referred to jointly as UW participants. These patients were referred for clinical genetic counseling and genetic testing and tended toward early age of onset of CRC/P or a positive family history. The parent CSER study on high throughput sequencing of CRC/P patients did not enroll individuals for whom clinical usual care recommendations were to pursue a single-gene test, rather than a broader gene panel (Gallego et al. 2016, 515-519) . Research on these cases was approved by the biomedical IRB committee at the UW and participants granted permission for broad sharing of genomic and phenotypic data by informed consent documentation. WHI participants were ascertained through the observational WHI study (The Women's Health Initiative Study Group 1998, 61-109) . Case status was defined as having a diagnosis of CRC before age 65 (UW, WHI), and/or ≥ 10 adenomatous polyps (lifetime total) (UW only) (Table 1) . A convenience sample of 2512 EA control participants (ESP) was ascertained from the NHLBI GO Exome Sequencing Project (see "Web resources") (Amendola et al. 2015, 305-315) . Individuals younger than 30 or with body mass index (BMI) > 50 were excluded as CRC/P rarely presents before age 30 and high BMI is associated with an increased risk for CRC/P. BMI ranged between 15 and 49.8 with a mean of 27.6. Cancer and polyp phenotypes for these ESP control individuals was unknown, therefore, it is possible that some have a history of CRC/P. Demographic information for the controls is given in Table 1 .
Participants: subsequent cohorts
A second cohort of deceased EA CRC patients was ascertained through the ColoCare study (CoCa, N = 73) (Yuan et al. 2017 (Yuan et al. , 1202 (Yuan et al. -1210 . These patients were newly diagnosed between the ages of 18 and 80, and had not had genetic testing (Table 1) .
For further comparison, we used two additional, publicly available data sets. We used a cohort consisting of 7325 EA women from the FLOSSIES data set (see "Web resources") (Walsh et al. 2010, 12629-12633; Wang et al. 2015, 926-937; Li et al. 2008 Li et al. , 1100 Li et al. -1104 . These women were over 70 years of age, had no history of a cancer diagnosis and were sequenced for genes on the BROCA panel, which includes genes known to be associated with CRC/P as well as genes associated with breast, ovarian, prostate, pancreatic, and renal cancers (Walsh et al. 2010 (Walsh et al. , 12629-12633, 2011 Nord et al. 2011, 184; Metzker 2010, 31-46; Shirts et al. 2016, 974-981) . Additionally, we used frequency summary data from the Exome Aggregation Consortium (ExAC), with the Cancer Genome Atlas (TCGA) subset removed (non-TCGA-ExAC) (see "Web resources"). This data set consists of 53,105 individuals (27,173 EA) with whole exome data, who were ascertained at multiple sites for many different traits, excluding individuals from TCGA (Lek et al. 2016, 285-291) . We used these cohorts and the cases to perform one-sided Fisher's exact tests comparing the expected frequency of PDVs for some of the genes of interest.
Next-generation sequencing and genotype calling
Cases were sequenced on Roche NimbleGen SeqCap EZ v3 (UW, CoCa) and Agilent SureSelect All Exon v5 (WHI). ESP Controls were sequenced on Agilent SureSelect Human All Exon Kit v2, Nimblegen RefSeq/CCDS design, or SeqCap EZ v1, divided among two centers: Broad institute (N = 1122) and Nickerson UW lab (N = 1390). As the target regions differed, we focused attention on the regions covered by all targets. To avoid an effect of different sequencing centers used for the UW/WHI cases and ESP controls, on the analysis, we only included variants that were genotyped in > 90% of the participants and had depth of coverage > 20 for at least 80% of the participants. The UW/WHI cases and ESP control genotypes were jointly called, simultaneously, using Genome Analysis Toolkit (McKenna et al. 2010 (McKenna et al. , 1297 (McKenna et al. -1303 Van der Auwera et al. 2013, 33; Poplin et al. 2017) . Details of the genotyping and quality control methods are in the supplemental methods. Individual level quality control measures resulted in the removal of 18 ESP controls from the analysis, leaving 2494 ESP controls. The resulting, filtered, high-confidence genotype data was annotated using SeattleSeqAnnotation138 (Ng et al. 2009, 272-276; Lek et al. 2016, 285-291) . Further annotation was obtained from ClinVar and HGMD (Stenson et al. 2009, 13; Landrum et al. 2016, 862) . Variants were determined to be pathogenic Amendola et al. (2015, 305-315) and Richards et al. (2015, 405-424 Table 2 ). European ancestry of all cases was confirmed using principal component analysis (PCA) (see Supplemental Methods). The same methods for joint genotyping, quality control, and confirmation of EA ancestry were used on the second case cohort. As the exome sequences for the CoCa cases were collected at a much later date, their genotypes were called separately from the first set of cases and the ESP controls. All 73 CoCa cases passed quality control and none of them harbored a pathogenic variant in any of the 16 known CRC/P genes listed above. Nineteen CoCa cases (26%) had at least one VUS in the 16 known CRC/P genes (Supplemental Table 2 ).
Genes and variation of interest
We focused the enrichment analysis on 158 genes collected from multiple sources and with varying supportive evidence for a role in CRC/P (Supplemental Table 3 ). This evidence derives from GWAS tagging SNPs (N = 12), loss of function and linkage (N = 12), known somatic involvement (N = 2), or involvement in DNA repair pathways according to (Smith et al. 2013 (Smith et al. , 1026 (Smith et al. -1034 (N = 133) . Several of these genes are a priori known to be associated with other cancers. It is expected that those genes that have evidence derived from linkage or are involved in other cancers are more likely candidates. However, we chose to keep a broader set of genes to allow for lower penetrance genes. We limited our analyses to potentially disruptive variation (PDV) to focus on the most relevant variants, which may increase power to detect an effect. We defined a PDV as having a minor allele frequency (MAF) < 0.005 in the ESP controls and all published populations in gnomAD (Lek et al. 2016, 285-291 ) (see "Web resources"), and to likely cause a change in the protein product, such as a stop gain (SG), frameshift (FS), splice acceptor (SA) or splice donor (SD) change. Early terminations (SG, FS) that resulted in a termination codon within 50 base pairs of the 3′ end of the penultimate exon, or occurred within the last exon, were excluded from the analysis as they are expected to result in a functional protein.
Statistical methods
We took a stepwise approach to testing for enrichment of PDVs in the 158 tested genes among the UW/WHI cases vs. the ESP controls. First, we performed a global, one-sided test across all the considered genes, to test the alternative hypothesis that the number of PDV heterozygotes in UW/ WHI cases would be higher than in the ESP controls. Second, we compared the distribution of the coding changes between these cases and controls. Finally, we used logistic regression to perform one-sided burden tests for each gene, adjusting for the first 5 principal components of ancestry (PCs) (see Supplemental Methods). We used a Bonferroni correction to determine significance for single-gene comparisons.
We further tested the alternative hypothesis that the overall frequency of PDV heterozygotes in the second case cohort (CoCa) would be higher than the frequency found in the ESP controls, above. In this situation, we are not accounting for the variation in the estimated frequency in the controls, and are assuming the estimate is representative of EA individuals, in general.
Finally, we compared the frequency of PDVs in specific genes in all cases to the observed total frequency of PDVs in EA cohorts from the FLOSSIES and non-TCGA ExAC data sets using Fisher's exact test. All statistical analyses were performed using the R 3.1.0 package(R Core Team 2016). All tests are one-sided, unless otherwise indicated.
Results
PDVs in UW/WHI cases vs. ESP controls
The UW/WHI cases had a statistically significant greater proportion of PDV heterozygotes in the genes tested than the ESP controls, with an odds ratio (OR) of 1.9, 95% CI (1.2, ∞) (one-sided Fisher's exact test p value = 0.02). Specifically, 17 cases (20%) had a PDV in a total of 16 genes (Table 2) . One case had two PDVs: one in BRCA2 [MIM 600185] and one in NTHL1. The same PDV in NTHL1, rs150766139, was found in two separate cases. Two genes, POLQ [604419] and RECQL [600537], had two unique PDVs each in the cases. In contrast, only 11.5% of controls (N = 282) had a PDV in a total of 84 genes (Supplemental Table 4 ). Seventeen controls had two PDVs each, and 1 3 49 genes had multiple PDVs in the controls (Supplemental Fig. 1 ). The NTHL1 PDV observed in two cases (2.4%), rs150766139, was found in four controls (0.16%). Both RECQL variants observed in the cases were each seen in a control (0.04%) and one POLQ variant observed in the cases (NM_199420.3:c.2021dupA) was seen in one control (0.04%). Sensitivity analyses removing splice variants from the analysis gave similar results (OR = 2, 95% CI (1.1, ∞), p = 0.02), as did reducing the MAF cutoff to 0.001 (OR = 2, 95% CI (1.1, ∞), p = 0.01).
A total of 237 unique PDVs (93 FS; 99 SG; 20 SA; 25 SD) were observed in the UW/WHI cases and ESP controls in 84 (53%) genes. Although the cases have a higher proportion of FS than the controls (Supplemental Table 5 ), the distribution of PDV types is not statistically significantly different between cases and controls (p > 0.5). Seven PDVs (3 FS, 3 SG, 1 SD) were observed in both cases and controls.
PDVs in CoCa cases
Thirteen CoCa cases (18%) were heterozygous for a PDV, which is statistically significantly different from the 11.5% observed in the ESP controls (t test p = 0.02, Table 3 ). Of these 13 PDVs (6 FS; 6 SG; 1 SA), the POLK frameshift, NM_016218.2:c.1243delA, was also observed in the UW/ WHI cases and in seven ESP controls.
Single-gene tests in the UW/WHI cases and ESP controls
There were 16 genes with PDVs in the UW/WHI cases; we performed logistic regression analyses between the UW/WHI cases and ESP controls for each. Three genes were significantly associated with case status, adjusting for multiple testing using a Bonferroni correction: NTHL1 (p = 0.0001), BRCA2 (p = 0.01) and BRIP1 (p = 0.04). One gene, RECQL, had suggestive evidence for association with case status, based on unadjusted p value of 0.02 (Bonferroni corrected p = 0.15). In all models, the first 5 PCs, were significant with difference in deviance of 327.77 on 5 degrees of freedom (χ 2 test p < 2e−16). 
Single-gene tests in all cases vs FLOSSIES and ExAC controls
We further compared the frequency of PDVs at seven genes among all cases (UW/WHI/CoCa) with that observed in the FLOSSIES and non-TCGA ExAC data (Table 4) . This list of genes included BRIP1 and genes with at least two heterozygous cases and no, or few, heterozygous ESP controls. The total frequency of PDVs was not significantly higher in the cases than the FLOSSIES or ExAC controls, for any single gene, under the assumption that the PDVs are independent of each other within each gene.
Non-CRC/P actionable findings
As the list of 158 genes studied here contains genes known to be associated with other cancers, it was possible to identify individual heterozygous for a pathogenic or likely pathogenic variant in such genes (Tables 2, 3 
Discussion
Overall, both the UW/WHI and CoCa CRC/P case cohorts carried a significantly higher fraction of PDVs than controls in the 158 genes hypothesized to be associated with CRC/P. Three genes (NTHL1, BRCA2, and BRIP1) had variants associated with case status, adjusting for ancestry principal components and multiple testing. Support for an association between NTHL1 and CRC/P via a recessive mode of inheritance was reported by others during the course of this study (Weren et al. 2015, 668-671; Helgason et al. 2015, 906-910) . Perhaps incidentally, a known BRCA2 pathogenic variant was identified in one of the two cases in our study with a PDV in NTHL1. Overall, our study supports the association of NTHL1 with CRC/P, but our design does not address mode of inheritance. Interestingly, both BRCA2 and BRIP1 are associated with increased breast and/ or ovarian cancer risk (Rafnar et al. 2011 (Rafnar et al. , 1104 (Rafnar et al. -1107 Ford et al. 1998, 676-689; Antoniou et al. 2003 Antoniou et al. , 1117 Antoniou et al. -1130 , and we found pathogenic variants for these genes in one female with CRC/P (age at last evaluation 49 years) without a personal history of either cancer, as well as in two males with CRC/P (ages at last evaluation 59 and 66 years). This suggests that these genes may be associated with a cancer syndrome that includes CRC/P, possibly at lower penetrance. In addition, we found a PDV in each of ATM and FANCM, two genes known to be associated with autosomal-dominant inheritance of breast cancer in two other CRC/P cases without a personal history of breast cancer: one male (age at last evaluation 75 years) and one female (age at last evaluation 46 years), respectively (Swift et al. 1987 (Swift et al. , 1289 (Swift et al. -1294 Kiiski et al. 2014, 15172-15177; Peterlongo et al. 2015, 5345-5355) . These findings of an association with CRC/P for genes associated with breast and/or ovarian cancer are in alignment with that of AlDubayan et al. (2018) . That study included a larger sample size and focused on a smaller set of genes known a priori to be associated with other heritable cancers and involved in DNA repair. In contrast, due to the small sample size of cases in our study, there is limited power to detect a significant difference in the frequency of PDVs for any single gene when comparing with the FLOSS-IES or non-TCGA ExAC control data sets. In addition to the small number of cases, our study is limited by reduced power. First, several cases and controls that remained in the analysis had a VUS in a gene known to be associated with CRC/P; a subset of these variants may be pathogenic. Second, exome sequencing can detect point mutations and small indels, but cannot detect genetic rearrangements or interference from pseudoegenes. Therefore, our analysis may have not detected some pathogenic variants. Third, the ESP control participants, for whom we did not have phenotypes, and the non-TCGA ExAC data set likely included individuals with CRC/P or other cancers which lowered our power to detect a difference in the frequency of PDVs between cases and controls. To address this issue, we removed ESP control individuals with pathogenic variants in known CRC/P genes. However, we were unable to clean the ExAC data beyond removing the TCGA individuals. Fourth, the single-gene tests may also be limited by lower penetrance, lowering the power of the tests. One future strategy to increase power to test these genes is to perform joint linkage and association family testing, adjusting for the presence of the proband, where family members are available. This work demonstrates support for considering additional CRC/P-associated genes be included in CRC/P gene mutation panel tests on a research basis. The authors caution that these genes should be considered as research genes, in the context of CRC/P, and should not be used to direct clinical care for CRC/P at this time. Given the expectation of high locus heterogeneity with many genes having an effect on CRC/P risk, larger studies will be required to determine which genes account for the observed excess of PDVs in CRC/P cases vs. controls identified here.
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